Form 4/A for URGN UroGen Pharma Ltd.
Accepted 2023-02-28 00:00:00 ET · period of report 2022-10-21 · accession 0001437749-23-004868 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DAI | 2023-02-28 | 2022-10-21 | URGN | Nussbaum Ran | Dir | M - OptEx | $5.94 | +48.0K | 1.49M | +3% | +$285.1K |
| DMAI | 2023-02-28 | 2022-10-21 | URGN | Nussbaum Ran | Dir | M - OptEx | $0.00 | -48.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-10-21 | M | A | 47,999 | $5.94 | 1,485,168 | I Managing member of entities affiliated with Pontifax Management III G.P. (2011) Ltd | — | — | (F1) On October 25, 2022, the reporting person filed a Form 4 that inadvertently reported 1,481,927 shares of securities beneficially owned following reported transaction instead of 1,485,168 shares. |
| 2 | Derivative | Stock Option (right to buy) | 2022-10-21 | M | D | 15,276 | $0.00 | 0 | I By Pontifax Cayman III Limited Partnership | $5.94 · 2018-12-27 to 2022-12-27 | 15,276 Ordinary Shares | |
| 3 | Derivative | Stock Option (right to buy) | 2022-10-21 | M | D | 32,723 | $0.00 | 0 | I By Pontifax (Israel) III Limited Partnership | $5.94 · 2018-12-27 to 2022-12-27 | 32,723 Ordinary Shares |